Trial Profile

A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Angiomyolipoma; Astrocytoma; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Endometrial hyperplasia; Glioma; Head and neck cancer; Hodgkin's disease; Liver cancer; Multiple myeloma; Neuroendocrine tumours; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Plexiform neurofibroma; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Tuberous sclerosis
Focus Pharmacokinetics
Sponsors Novartis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com